Siddhanti, who joined the biopharmaceutical company in 2017, previously served as Vice President of Business Development. His tenure has been marked by high-stakes transactional work, most notably leading the recent $2.9 billion acquisition of Soleno Therapeutics. Beyond corporate development, he provides strategic oversight for the company’s muscarinic portfolio, including the development of direclidine for schizophrenia and bipolar disorder.
In section Releases
Samir Siddhanti Named Chief Business Officer at Neurocrine Biosciences
After seven years of steering key strategic partnerships, Samir Siddhanti has been promoted to Chief Business Officer at San Diego-based Neurocrine Biosciences. Siddhanti now joins the company’s executive management committee, where he will oversee enterprise growth, corporate strategy, and the continued expansion of the firm’s clinical drug pipeline.
Chief Executive Officer Kyle W. Gano credited Siddhanti with shaping the company’s long-term trajectory through disciplined capital allocation and portfolio prioritization. Before his time at Neurocrine, Siddhanti worked in biotechnology equity research at Goldman Sachs and holds advanced degrees in Management Science and Engineering from Stanford University. In his new capacity, he will focus on integrating internal innovation with external opportunities to bolster the firm’s commercial reach.
Comments (0)
No comments yet. Be the first!